Available Forms: Oral Solution
Available Strengths: 2.2 mg/mL, 5 mg/mL
Reference Brands: Fintepla (USA, EU)
Category: Neurology
Fenfluramine hydrochloride is an antiepileptic medication used for the treatment of seizures associated with Dravet syndrome and Lennox–Gastaut syndrome in patients aged two years and older. It works by modulating serotonergic activity in the brain, helping reduce the frequency and severity of seizures. Fintepla is available as an oral solution in 2.2 mg/mL and 5 mg/mL strengths, with dosing customized to patient needs under strict monitoring programs.
Quick Response Guaranteed | Verified Suppliers
Fenfluramine hydrochloride is used to treat seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients two years of age and older. It helps reduce the frequency and severity of seizures when used in combination with other antiepileptic medications. Previously, fenfluramine was used as an appetite suppressant, but its use for weight loss was discontinued due to cardiac side effects.
Fenfluramine hydrochloride is made from the active ingredient fenfluramine hydrochloride, a serotonin-releasing agent that also modulates sigma-1 receptors in the brain, helping to stabilize neuronal activity and reduce seizure episodes. Its chemical name is (±)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine hydrochloride. Inactive ingredients may vary depending on the formulation and manufacturer.
The trade name of fenfluramine hydrochloride is Fintepla.
Fenfluramine hydrochloride (Fintepla) is manufactured and marketed by UCB Pharma (formerly by Zogenix Inc., which was acquired by UCB).
The generic name of the drug is fenfluramine hydrochloride.
The brand name of fenfluramine hydrochloride is Fintepla.
Fenfluramine hydrochloride is manufactured in Europe and the United States by UCB Pharma and its licensed facilities. It is also distributed in other regions under regulatory approval for epilepsy treatment.
Strength: 125 mg/mL, 200 mg, 250 mg, 300 mg, 500 mg, 100 mg/mL
Form: Tablet / Capsule/ Injection / Oral syrup
Reference Brands: Depakene (USA), Depakine (EU/LATAM), Valprol (India)
Strength: 50 mg, 100 mg
Form: Tablets
Reference Brands: Ubrelvy (USA/India)
Strength: 100 mg
Reference Brands: Tasmar (USA/EU)
Strength: 50 mg ,100 mg
Reference Brands: Xadago (USA/EU)
By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under ‘Fair use.’
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Stay updated on pharma trends and marketplace opportunities.
Online · B2B Pharma · Medical Tourism · NPP